Linical Co., Ltd. (2183) AI Stock Analysis

• Market Cap: ¥7.36B
• Dividend Yield: 4.91%
• Average Volume (3M): 13.72K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.57
• Revenue Growth: -15.20%
• EPS Growth: -259.37%
• Country: JP
• Employees: 662
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -9.84
• Shares Outstanding: 24,740,000
• 10 Day Avg. Volume: 19,130
• 30 Day Avg. Volume: 13,720
• PEG Ratio: 0.58
• Price to Book (P/B): 2.08
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 8.62
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥311.00
• Price Target Upside: -4.60% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 54 Neutral
• Price Target: ¥311.00 ▼(-4.60%Downside)

The overall stock score is primarily influenced by moderate financial performance with declining revenues and losses. Technical analysis indicates moderate positive momentum, while valuation reflects challenges with negative earnings but a high dividend yield. The absence of significant earnings call insights and corporate events limits additional impacts on the score.

Linical Co., Ltd. Business Overview & Revenue Model

Company Description

Linical Co., Ltd. is a Contract Research Organization (CRO) that operates primarily in the pharmaceutical and biotechnology sectors. The company provides a comprehensive portfolio of services, including clinical trial management, data management, pharmaceutical development, and regulatory consulting. Linical is dedicated to supporting the development and commercialization of pharmaceutical products globally, with a strong presence in Europe, Asia, and North America.

How the Company Makes Money

Linical Co., Ltd. generates revenue by offering a wide range of CRO services to pharmaceutical and biotechnology companies. The company earns money primarily through service contracts for clinical trial management, where it assists with the design, execution, and monitoring of clinical studies. Additional revenue streams include data management services, regulatory consulting to ensure compliance with regional and international guidelines, and pharmaceutical development support. Linical's earnings are influenced by its ability to secure long-term contracts with major pharmaceutical companies and its strategic partnerships, which enable it to expand its global reach and service offerings.

Linical Co., Ltd. Financial Statement Overview

Summary

Linical Co., Ltd. exhibits challenges in profitability with declining revenues and losses impacting the income statement. The balance sheet remains stable with moderate leverage and strong liquidity. Cash flows are positive but declining, underscoring the need for improved operational performance to sustain financial health.

Income Statement

The income statement shows declining performance with total revenue decreasing from the previous year, leading to negative net income in the latest period. The gross profit margin is approximately 19.23%, but the net profit margin is negative due to the loss. Revenue growth has been inconsistent, with a significant drop in the most recent period, and EBIT and EBITDA margins have deteriorated.

Balance Sheet

The balance sheet indicates moderate strength with a stable equity base, though the debt-to-equity ratio is approximately 0.32, suggesting moderate leverage. The equity ratio is around 43.24%, providing a reasonable cushion against liabilities. However, the net debt position is negative, indicating strong liquidity.

Cash Flow

Cash flow analysis reveals declining free cash flow, but it remains positive. Free cash flow to net income ratio is not applicable due to negative net income, but the operating cash flow to net income ratio is positive, indicating operational cash generation despite financial losses.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	11.01B	10.44B	12.31B	12.52B	11.56B	10.28B
Gross Profit	2.57B	2.01B	3.78B	4.16B	3.61B	2.77B
EBITDA	206.58M	40.97M	1.20B	1.89B	1.50B	801.38M
Net Income	-232.20M	-539.10M	338.27M	1.00B	790.49M	539.97M
Balance Sheet
Total Assets	17.40B	16.78B	18.54B	17.46B	15.72B	15.28B
Cash, Cash Equivalents and Short-Term Investments	6.77B	7.04B	7.47B	7.04B	5.99B	5.08B
Total Debt	2.43B	2.33B	2.90B	3.54B	4.10B	4.69B
Total Liabilities	9.72B	9.52B	10.30B	9.88B	9.17B	9.57B
Stockholders Equity	7.68B	7.25B	8.24B	7.58B	6.54B	5.71B
Cash Flow
Free Cash Flow	0.00	602.21M	1.03B	1.83B	1.59B	-44.89M
Operating Cash Flow	0.00	605.10M	1.06B	1.84B	1.63B	23.61M
Investing Cash Flow	0.00	-54.93M	-28.00M	-14.19M	20.76M	169.00M
Financing Cash Flow	0.00	-939.22M	-960.92M	-957.33M	-951.55M	-329.56M

Linical Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 326.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2183, the sentiment is Positive. The current price of 326 is below the 20-day moving average (MA) of 329.15, above the 50-day MA of 319.82, and above the 200-day MA of 324.73, indicating a bullish trend. The MACD of 2.67 indicates Positive momentum. The RSI at 55.96 is Neutral, neither overbought nor oversold. The STOCH value of 44.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:2183.

Linical Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	65 Neutral	¥355.44B	11.10	-2.99%	2.49%	11.76%	-10.16%
4584	55 Neutral	¥13.82B	―		―	109.03%	98.53%
2183	54 Neutral	¥7.36B	―		4.91%	-15.20%	-259.37%
3750	54 Neutral	¥8.06B	55.07		―	-92.17%	-1648.96%
4564	47 Neutral	¥8.83B	―	-148.36%	―	22.93%	47.73%
4893	41 Neutral	¥7.53B	―		―	-97.61%	14.80%

Linical Co., Ltd. Corporate Events

Linical Co., Ltd. Announces Year-End Dividend Distribution

Linical Co., Ltd. announced a resolution to distribute retained earnings, declaring a year-end dividend of JPY 16.00 per share for the fiscal year ended March 31, 2025. This decision reflects the company’s commitment to balancing corporate growth with shareholder returns, as dividends are paid from retained earnings based on board resolutions.

Linical Co., Ltd. Reports Financial Downturn with Optimistic Forecast for 2026

Linical Co., Ltd. reported a significant decline in its financial performance for the fiscal year ending March 31, 2025, with net sales dropping by 15.2% and a net loss of ¥539 million. Despite the downturn, the company forecasts a recovery in the next fiscal year with an expected 7.3% increase in net sales and a return to profitability.